Eupraxia Pharmaceuticals Inc (EPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) has a cash flow conversion efficiency ratio of -0.037x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-4.51 Million ≈ $-3.26 Million USD) by net assets (CA$123.06 Million ≈ $89.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eupraxia Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EPRX liabilities breakdown for a breakdown of total debt and financial obligations.
Eupraxia Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eupraxia Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JSL S.A
SA:JSLG3
|
0.419x |
|
Shanghai Rychen Technologies Co. Ltd. A
SHE:301273
|
N/A |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
-0.025x |
|
Chieftek Precision Co Ltd
TW:1597
|
0.009x |
|
BNY Mellon Strategic Municipals Inc
NYSE:LEO
|
0.008x |
|
Acacia Research Corporation
NASDAQ:ACTG
|
0.017x |
|
Ambac Financial Group Inc
NYSE:AMBC
|
-0.036x |
|
Xinjiang Tianshun Supply Chain Co Ltd
SHE:002800
|
-0.079x |
Annual Cash Flow Conversion Efficiency for Eupraxia Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Eupraxia Pharmaceuticals Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Eupraxia Pharmaceuticals Inc (EPRX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$45.77 Million ≈ $33.11 Million |
CA$-29.99 Million ≈ $-21.70 Million |
-0.655x | +97.24% |
| 2023-12-31 | CA$1.18 Million ≈ $851.15K |
CA$-27.92 Million ≈ $-20.19 Million |
-23.726x | -1335.90% |
| 2022-12-31 | CA$11.36 Million ≈ $8.22 Million |
CA$-18.78 Million ≈ $-13.58 Million |
-1.652x | -120.66% |
| 2021-12-31 | CA$19.55 Million ≈ $14.14 Million |
CA$-14.64 Million ≈ $-10.59 Million |
-0.749x | -4116.12% |
| 2020-12-31 | CA$-21.66 Million ≈ $-15.67 Million |
CA$-403.93K ≈ $-292.19K |
0.019x | -93.46% |
| 2019-12-31 | CA$-18.13 Million ≈ $-13.12 Million |
CA$-5.17 Million ≈ $-3.74 Million |
0.285x | -60.80% |
| 2018-12-31 | CA$-11.44 Million ≈ $-8.27 Million |
CA$-8.32 Million ≈ $-6.02 Million |
0.728x | +170.13% |
| 2017-12-31 | CA$5.11 Million ≈ $3.69 Million |
CA$-5.30 Million ≈ $-3.83 Million |
-1.038x | -- |
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more